Meeting slides
Suggested Readings

2022 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

The Alzeimer's disease clinical spectrum: diagnosis and management.

Atri A. Med Clin North Am. 2019;103(2):263-293.

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

Two randomized phase 3 studies of aducanumab in early Alzheimer's disease.

Budd Haeberlein S, Aisen PS, Barkhof F. et al. J Prev Alzheimers Dis. 2022;9 (2): 197-210.

Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.

Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.

Assessment of a plasma amyloid probabilty score to estimate amyloid positron emission tomography findings among adults with cognitive impariment.

Hu Y, Kirmess KM, Meyer MR, et al. JAMA Netw Open. 2022;5(4):e228392.

Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.

Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

Molecular biomarkers of Alzheimer's disease: progress and prospects.

Lashley T, Schott JM, Weston P, et al. Dis Model Mech. 2018;11(5):dmm031781.

Neuroinflammation and microglial activiation in Alzheimer disease: where do we go from here?

Leng F, Edison P. Nat Rev Neurol. 2021;17(3):157-172.

Donanemab in early Alzheimer's disease.

Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691-1704.

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.

Palmqvist S, Tideman P, Cullen N, et al. Nat Med. 2021;27(6):1034-1042.

Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.

Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.

Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.

Salloway S, Chalkias S, Barkhof F, et al. JAMA Neurol. 2022;79(1):13-21.

Cognitive assessment of Alzheimer's disease and dementias in clinical practice: pragmatics of brief instruments and neuropsychological evaluation. 

Shaughnessy L, Sheard S, Goldfarb D, Atri A. J Clin Psychiatry. 2019;8-(4):MS18002Br2C. 

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Res Ther. 2021;13(1):80.

What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?

Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.

Economic burden of Alzheimer disease and managed care considerations.

Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Related activities
1.00 CME/CE

Clinical Issues in Alzheimer’s Disease

Debates and Discussions About Diagnosis, New Therapies, and Health Care Delivery

Faculty: Alireza Atri, MD, PhD; Sharon Cohen, MD; Marwan Sabbagh, MD
Release: 08/17/2022
Expiration: 08/17/2023